EX-FILING FEES 5 d656211dexfilingfees.htm EX-FILING FEES EX-FILING FEES

Exhibit 107

Calculation of Filing Fee Tables

Form S-3

(Form Type)

Enanta Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities and Carry Forward Securities

 

                 
    

Security

Type(1)

 

Security

Class

Title

  Fee
Calculation
or Carry
Forward
Rule
  Amount
Registered(1)(2)
  Proposed
Maximum
Offering
Price Per
Unit(2)
 

Maximum
Aggregate
Offering

Price

 

Fee

Rate

  Amount of
Registration
Fee
 
Newly Registered Securities
                 
Fees to Be Paid   Equity   Common Stock, par value $0.01 per share            
                 
    Equity   Preferred Stock, par value $0.01 per share            
                 
    Debt   Debt Securities              
                 
    Other   Warrants            
                 
    Other   Units(3)            
                 
    Unallocated (Universal) Shelf   Unallocated (Universal) Shelf   457(o)   (1)(2)   (2)   $150,000,000   0.00014760   $22,140
 
Carry Forward Securities
                 
Carry Forward Securities                
           
    Total Offering Amounts     $150,000,000   0.00014760   $22,140
           
    Total Fees Previously Paid        
           
    Total Fee Offsets         $9,270
           
    Net Fee Due               $12,870

 

(1)

This registration statement covers such indeterminate amount or number of the securities of each identified class as the registrant may from time to time issue at indeterminate prices which shall have an aggregate initial offering price not to exceed $150,000,000, including securities issuable upon conversion, exercise, exchange, redemption, repurchase or settlement of other securities. Pursuant to Rule 416 under the Securities Act of 1933, as amended, or the Securities Act, this Registration Statement shall also cover any additional securities issuable by reason of any stock split, stock dividend or similar transaction, including anti-dilution provisions.

(2)

The proposed maximum offering price per unit for the primary offering will be determined, from time to time, by the registrant in connection with the issuance by the registrant of the securities registered hereunder and is not specified as to each class of security pursuant to General Instruction II.D. of Form S-3 under the Securities Act.

(3)

Each unit will represent an interest in two or more other securities, which may or may not be separable from one another.


Table 2: Fee Offset Claims and Sources

 

                       
    

Registrant

or Filer

Name

 

Form

or

Filing

Type

 

File

Number

 

Initial

Filing

Date

 

Filing

Date

  Fee
Offset
Claimed
  Security
Type
Associated
with Fee
Offset
Claimed
  Security
Title
Associated
with Fee
Offet
Claimed
  Unsold
Securities
Associated
with Fee
Offset
Claimed
 

Aggregate
Offering

Amount
Associated

with Fee

Offset

Claimed

 

Fee

Paid

with

Fee
Offset
Source

 
Rule 457(p)
                       
Fee Offset Claims   Enanta Pharmaceuticals, Inc.   424(b)(5)   333-258632   August 26, 2022     $9,270 (1)   Equity   Common Stock, par value $0.01 per share   (1)   $100,000,000    
                       
Fee Offset Sources   Enanta Pharmaceuticals, Inc.   424(b)(5)   333-258632       August 26, 2022                       $9,270

 

(1)

On August 26, 2022, the registrant filed a prospectus supplement (the “2022 Prospectus Supplement”) to the prospectus included in its Registration Statement on Form S-3 (Registration Statement No. 333-258632) (the “2021 Registration Statement”) and concurrently submitted a fee of $9,270. The 2022 Prospectus Supplement related to the registrant’s offer and sale from time to time of shares of the registrant’s common stock, par value $0.01 per share, having an aggregate gross sales price of up to $100,000,000 from time to time under an at-the-market program. As of the date of this registration statement, the full $100,000,000 remains unsold under the at-the-market program. The 2021 Registration Statement and the offering that included the unsold securities under the 2022 Prospectus Supplement have been terminated. Pursuant to Rule 457(p) under the Securities Act, a registration fee credit of $9,270 is available to offset the current registration fee.